Research Interests:
My current research focuses on determining how targeted and cytotoxic chemotherapy impact the brain and how drug transporters contribute to these effects. Consistent with this research, I am interested in the translational pharmacology of anticancer therapeutics, especially characterizing the preclinical and clinical PK/PD of select agents.
Biosketch:
Trainees:
Bob Weber – Graduate Student
Recent Publications:
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD*, Blaser BW*. BMX kinase mediates gilteritinib gesistance in FLT3-mutated AML through microenvironmental factors. Blood Adv. 2022 Sep 13;6(17):5049-5060. doi: 10.1182/bloodadvances. 2022007952. *Co-senior authors (IF, 6.5)
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim J-G, Sparreboom A, Savona MR, Mims AS, Baker SD. Interaction of antifungal drugs with CYP3A-and OATP1B-mediated venetoclax elimination. Pharmaceutics. 2022 Mar 23;14(4):694. doi: 10.3390/pharmaceutics14040694. (IF, 6.29)
Eisenmann ED, Stromatt JC, Fobare S, Huang KM, Buelow DR, Orwick S, Jeon JY, Weber RH, Larsen B, Mims AS, Hertlein E, Byrd JC, Baker SD. TP-0903 Is active in preclinical models of acute myeloid leukemia with TP53 mutation/deletion. Cancers. 2022 Dec 21;15(1):29. doi: 10.3390/cancers 15010029. (IF, 6.32)
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B. Molecules. 2022 Oct 12;27(20):6815. doi: 10.3390/molecules27206815. (IF, 4.927)
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov 1;1210:123437. doi: 10.1016/j.jchromb.2022.123437. (IF, 3.205)
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. A Metabolomics approach for predicting OATP1B-Type transporter-mediated drug-drug interaction liabilities. Pharmaceutics. 2022 Sep 13;14(9):1933. doi: 10.3390/ pharmaceutics14091933. (IF, 6.29)
Uddin ME, Eisenmann ED, Huang KM, Garrison DA, Talebi Z, Gibson AA, Jin Y, Nepal M, Bonilla IM, Fu Q, Miller A, Tarasovc M, Jay CE, Cui X, Einolf HJ, Pelise RM, Smith S, Radwanski P, Sweet DH, König J, Fromm MF, Carnes CA, Hu S, Sparreboom A. MATE1 deficiency exacerbates dofetilide-induced proarrhythmia. Int J Mol Sci. 2022 Aug 3;23(15):8607. doi.org/10.3390/ijms23158607. (IF, 6.208)